As it relates to ALK-rearranged NSCLC, there are a few studies examining the benefit of neoadjuvant/perioperative crizotinib, ceritinib, and alectinib in resectable, ALK-rearranged NSCLC. Here, ALK is linked to non-small cell lung carcinoma.